These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23410145)

  • 21. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
    Amole CD; Middlecote C; Prabhu VR; Kumarasamy N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):390-397. PubMed ID: 28441147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negotiating antiretroviral drug prices: the experience of the Andean countries.
    Seoane-Vazquez E; Rodriguez-Monguio R
    Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.
    Sapsirisavat V; Vongsutilers V; Thammajaruk N; Pussadee K; Riyaten P; Kerr S; Avihingsanon A; Phanuphak P; Ruxrungtham K;
    PLoS One; 2016; 11(6):e0157039. PubMed ID: 27322409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The make or buy debate: considering the limitations of domestic production in Tanzania.
    Wilson KR; Kohler JC; Ovtcharenko N
    Global Health; 2012 Jun; 8():20. PubMed ID: 22747578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing equitable antiretroviral allocation strategies in resource-constrained countries.
    Wilson DP; Blower SM
    PLoS Med; 2005 Feb; 2(2):e50. PubMed ID: 15737005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
    Dhamija P; Bansal D; Medhi B
    Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.
    Waning B; Kyle M; Diedrichsen E; Soucy L; Hochstadt J; Bärnighausen T; Moon S
    Global Health; 2010 May; 6():9. PubMed ID: 20500827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable Populations.
    Tsuyuki K; Surratt HL; Levi-Minzi MA; O'Grady CL; Kurtz SP
    AIDS Behav; 2015 May; 19(5):857-68. PubMed ID: 25092512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.
    Alpern JD; Zhang L; Stauffer WM; Kesselheim AS
    Clin Infect Dis; 2017 Nov; 65(11):1848-1852. PubMed ID: 29020146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
    Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
    Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
    Adesina A; Wirtz VJ; Dratler S
    Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is greater generic competition also linked to lower drug prices in South Korea?
    Son KB
    Health Econ Rev; 2020 Sep; 10(1):30. PubMed ID: 32930889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.